Skip to main content

Moderna says it expects up to $15 billion in sales of Covid, RSV, flu vaccines in 2027

Moderna said it sees a corresponding operating profit from its Covid, RSV, and flu vaccines in the range of $4 billion to $9 billion in 2027.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.